ANI Pharmaceuticals Inc. - 10-Q Summary (Q2 2026)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company operating through two primary segments: Rare Disease and Brands (featuring Cortrophin Gel and the Alimera-acquired Retina Franchise including ILUVIEN) and Generics and Other. The company owns three manufacturing facilities in the U.S. and continues to expand its rare disease portfolio through organic growth and strategic acquisitions.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenues | $266.0 million | $211.4 million | $503.5 million | $408.5 million |
| Operating Income | $40.5 million | $13.9 million | $79.3 million | $40.1 million |
| Net Income | $24.7 million | $8.5 million | $54.2 million | $24.2 million |
| Diluted EPS | $1.05 | $0.36 | $2.32 | $1.05 |
| Operating Cash Flow (YTD) | $115.0 million (2026) vs $110.8 million (2025) | |||
| Cash & Equivalents | $360.2 million (as of June 30, 2026) | |||
| Total Debt (Net) | ~$301.5 million (Term Loan A) + $309.0 million (Convertible Notes) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 25.9% QoQ and 23.3% YTD, driven primarily by the Rare Disease and Brands segment (+41.2% QoQ).
- Cortrophin Gel Performance: Revenue from Cortrophin Gel surged 43.5% QoQ ($117.1M) due to market share gains and overall ACTH market growth.
- Harmony Agreement Impact: The segment recognized $17.7 million in royalties and milestone revenue in Q2 2026 from the Harmony Biosciences agreement, a new revenue stream not present in the prior year.
- ILUVIEN/YUTIQ Transition: Revenues from the Retina Franchise (ILUVIEN and YUTIQ) declined 16.1% QoQ as the company transitioned U.S. promotional efforts from YUTIQ to ILUVIEN (which now holds a combined label for DME and NIU-PS).
- Expense Management: Operating expenses increased 14.2% QoQ, largely due to higher Cost of Sales (34.2% increase) driven by volume growth and royalty-bearing products, and increased SG&A (12.1% increase) due to sales force expansion for acute gouty arthritis.
- Profitability: Operating margin improved significantly to 15.2% in Q2 2026 from 6.6% in Q2 2025.
Guidance, Outlook, and Risks
- Strategic Focus: Management is building a dedicated sales organization for acute gouty arthritis flares (Cortrophin Gel) and expanding the Rare Disease team. The company continues to evaluate acquisitions to complement its portfolio.
- Liquidity: The company maintains strong liquidity with $360.2 million in cash and $74.9 million available under its revolving credit facility. Management believes resources are sufficient for the next 12 months.
- Legal Proceedings:
- CG Oncology: ANI lost a jury verdict in Delaware regarding royalty disputes but intends to appeal to the Delaware Supreme Court.
- Ranitidine Litigation: ANI remains a defendant in MDL and state court personal injury litigation regarding NDMA; appeals are pending in the Eleventh Circuit.
- Patent Litigation: New patent infringement suits were filed in Q2 2026 involving Harmony Biosciences (vs. AET/Sandoz), Orphalan SA, and Xeris Pharmaceuticals (Levoketoconazole).
- Forward-Looking Risks: Risks include regulatory changes (e.g., One Big Beautiful Bill Act), supply chain dependencies (single-source API suppliers), and the outcome of ongoing litigation.
Investor Verification Checklist
- Verify the sustainability of Cortrophin Gel's 43.5% revenue growth rate and the impact of the new prefilled syringe format.
- Monitor the transition of the Retina Franchise (ILUVIEN/YUTIQ) and the timeline for revenue stabilization following the promotional shift.
- Review the status of the CG Oncology appeal and potential financial exposure from Ranitidine litigation.
- Assess the impact of the Harmony Agreement milestones on future revenue recognition.
- Confirm the company's ability to maintain margins as royalty-bearing product sales increase.